SAN FRANCISCO, CHICAGO, PRINCETON, January 21, 2022: Morgan Lewis represented Eli Lilly and Company on collaboration agreements with Abbisko Therapeutics Co. Ltd. and Evotec SE announced this week.
Under the collaboration and exclusive licensing agreement with Abbisko Therapeutics, the companies will advance further discovery, development, and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases. The drug discovery agreement with Evotec will focus on the field of metabolic diseases with a focus on kidney diseases and diabetes.
The Morgan Lewis life sciences transactions team advising Eli Lilly with respect to Abbisko included partner Ben Pensak and associate Ben Rho; the team advising on the Evotec agreement also included Ben and associate Natalie Nicelli.